86P Acute kidney injury in patients included in early-phase oncology clinical trials: Results of the AKITEP study
Acute kidney injury (AKI), defined by the KDIGO Consensus as an increase in serum creatinine of ≧ 0.3 mg/dl or ≧ 1.5 times baseline value, is prevalent in patients treated for cancers secondary to drug-induced toxicities, cancer complication and comorbidities. AKI is associated with poorer prognosis. No data exists on the prevalence of AKI in early-phase oncology trials (EPT), risk factors and impact on patient outcomes.
Authors
- Matthieu Roulleaux Dugage (ORCID: https://orcid.org/0000-0003-3192-2342)
- Karine Fréon (ORCID: https://orcid.org/0000-0001-7853-078X)
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Mélanie Guibourt
- Paul Matte (ORCID: https://orcid.org/0000-0003-4145-4335)
- C. Massard
- Matthieu Delaye (ORCID: https://orcid.org/0000-0002-2435-4757)
- François Lion
- C. Vincent
- Stevie Yeye
Institutions
- Institut Gustave Roussy (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104246
- Primary Topic
- Acute Kidney Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00